MetAlert (OTC: MLRT), a pioneer in location-sensitive health monitoring devices and wearable technology products, recently signed a letter of intent (“LOI”) with Sensio Group, a Norway-based provider of welfare technology and home automation solutions, for the marketing and distribution of RoomMate(TM). “RoomMate, one of MetAlert’s flagship products, is a wall-mounted alert system that delivers both efficiency and privacy. It detects and alerts caregivers about patient behavior that could lead to falls and injuries, using 3D infrared and wall-mounted sensors that eliminate the need for any other physical installations or wearables. Unlike more mainstream patient monitoring systems, RoomMate does not use cameras, and the collected images are not stored. Instead, its use of infrared maintains patient anonymity, while action logs help inform caregivers of any critical information they might need to know as they provide their services,” a recent article explains. “It is estimated that patients with Alzheimer’s, dementia and autism (‘ADA’) account for approximately 2.9% of the world’s population, equivalent to 34 million people in 24 developed countries. Given their unique issues, which include, but are not limited to, memory problems and adversity to wearing unknown items, traditional products such as Fitbits and iPhones do not provide a practical solution. Therefore, MetAlert has set out to solve this issue by creating devices specific to their use cases and designed to improve their overall quality of life.”
To view the full article, visit https://ibn.fm/7a3t3
About MetAlert Inc.
MetAlert is a pioneer in smart, mobile and wearable tracking and recovery location-based solutions, supported through a proprietary IOT enterprise monitoring platform and intellectual property portfolio. The company offers global end-to-end solutions of hardware, software and connectivity and develops two-way GPS tracking technologies, which seamlessly integrate with consumer products and enterprise applications, utilizing the latest in miniaturized, low power consumption GPS, cellular, RF, NFC, and BLE technology, enabling subscribers to track in real time the whereabouts of people or high value assets. MetAlert is known for its game-changing and award-winning patented GPS SmartSole – think Dr. Scholl’s meets LoJack, the world’s first visible wearable technology tracking device created for those at risk of wandering due to Alzheimer’s, dementia, autism and traumatic brain injury. MetAlert’s subscription based business model is built around technology innovation and the company holds dozens of patents, with many issued patents in the area of GPS tracking. The company has international distributors servicing customers across the globe with subscribers in over 40 countries and is a U.S. military government contractor. Other customers include public health authorities and municipalities, emergency and law enforcement, private schools, assisted living facilities, NGOs, small business enterprises, senior care homes, and consumers. For more information, visit the company’s website at www.MetAlert.com.
NOTE TO INVESTORS: The latest news and updates relating to MLRT are available in the company’s newsroom at https://ibn.fm/MLRT
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]
BioMedWire is part of the InvestorBrandNetwork